Alumis
ALMS27.0400.15% ( -0.040 )
Alumis (ALMS)
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company off...
- Open
- 27.370
- High
- 27.370
- Low
- 26.060
- Prev. Close
- 27.080
- Volume
- 474.18K
- Turnover
- 12.67M
- Avg Price
- 26.722
- Bid/Ask Ratio
- --
- Amplitude
- 4.84%
- 52wk High
- 31.350
- Volume Ratio
- 0.55
- Turnover Ratio
- 0.62%
Alumis Analyst Rating
View MoreForecast & Rating
Jul 21, 2026Price forecast
$40.1048.30%
Forecast & RatingStrong buy
11analysts
- Strong buy81.82%
- Buy9.09%
- Hold9.09%
- Sell0.00%
- Strong sell0.00%
News
- Market Beat · 6 hours ago
Short Interest in Alumis Inc. (NASDAQ:ALMS) Drops By 52.7%
- PUBT · Jul 8 at 03:41 PM
Alumis Chief Legal Officer Sanam Pangali disposes of common shares worth $140,000
- Tip Ranks · Jul 2 at 04:10 PM
Alumis Shareholders Reelect Directors and Ratify Auditor
- PUBT · Jul 2 at 03:32 PM
Alumis holds annual shareholder meeting
- rttnews · Jun 14 at 09:09 PM
Top Biotech Gainers: SNSE Awaits Data In 2H, STTK To Begin Crohn's Trial In Q3, ALMS On Watch
- Top Gainers&Losers · Jun 12 at 05:00 PM
Top 10 US Stock Gainers (6.12)
